logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Romosozumab for osteoporosis in men

< Back

Romosozumab for osteoporosis in men

Drugs

Musculoskeletal

May 2017


Romosozumab arose from a genetic discovery that revealed the body’s own natural ability to increase bone strength. It is a treatment which aims to block the activity of the protein sclerostin. This diminishes bone breakdown and removal and stimulates bone formation, thereby increasing bone strength. The effectiveness and safety of romosozumab for the treatment of osteoporosis in men has been studied in a phase III clinical trial. The study showed that romosozumab given by injection monthly for a 12 month period significantly increased the formation of new bones, reducing the risk of a fracture. Romosozumab was also found to be safe with no significant adverse effects.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts